Secondary safety analysis of a phase 3 trial of inavolisib plus palbociclib-fulvestrant in PIK3CA-mutated HR+/HER2- advanced breast cancer: hyperglycaemia led to inavolisib interruption in 27.2%, reduction in 2.5% and discontinuation in 0.6%.
RCT
Im et al. Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer